Introduction
Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous disorder of immune regulation characterized by impaired lymphocyte cytotoxicity (1) (2) (3) (4) . Four genetic defects associated with FHL have been identified. FHL-2 is caused by mutations in the PRF1 gene, which encodes Perforin 1, a pore-forming protein that is crucial for target cell lysis (5) .
The genes mutated in FHL-3 (UNC13D encoding MUNC13-4), FHL-4 (STX11 encoding SYNTAXIN11) and FHL-5 (STXBP2 encoding MUNC18-2) all encode proteins important for the intracellular trafficking and exocytosis of lytic granules containing perforin and other effector molecules of cell-mediated cytotoxicity (6) (7) (8) (9) . In the context of a relevant immunological trigger, impaired cytotoxicity leads to uncontrolled activation of cytotoxic T cells and macrophages resulting in a hyperinflammatory state characterized by T cell and macrophage infiltration of various organs including bone marrow, liver and the central nervous system (3) .
FHL patients usually present within the first two years of life with hemophagocytic lymphohistiocytosis (HLH), a life-threatening disease including prolonged fever, hepatosplenomegaly, pancytopenia and neurological symptoms as well as characteristic laboratory abnormalities such as elevated levels of serum triglycerides, ferritin and soluble Interleukin 2-receptor (sCD25) and low levels of fibrinogen (10). Histomorphological demonstration of hemophagocytosis in the bone marrow or other tissues is a typical, yet initially often absent feature of the disease. Flow cytometric analysis of Perforin expression and NK cell and CTL degranulation are helpful in supporting the rapid diagnosis of FHL (7, (11) (12) (13) , which needs then to be confirmed by genetic analysis. Unfortunately, since there are no characteristic prodromal signs, diagnosis in patients without other affected family members is usually not established before the first HLH episode. DOI: 10.3324/haematol.2010.029389 Due to increasing awareness of the signs and symptoms of HLH and a better understanding of the genetic basis of the disease, FHL has been increasingly diagnosed in patients presenting beyond infancy. These atypical presentations have been reported in adolescents and even in adults as late as 62 years of age (7, 8, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . They may be associated with milder and often recurrent HLH episodes and prolonged survival in the absence of hematopoetic stem cell transplantation (HSCT), which is unusual in patients with the typical disease. Atypical FHL is usually associated with missense or splice-site mutations in the affected genes (15, 23, 30) . A better characterization of these variant phenotypes of FHL can help to raise the clinical suspicion of FHL even in the absence of overt HLH. Moreover, the characterization of specific immunological parameters associated with early versus lateonset forms of FHL would facilitate an earlier diagnosis of FHL and help to guide treatment decisions including hematopoetic stem cell transplantation. At present, it is unclear whether a correlation between the degree of defective NK and CTL function and the age at onset of clinical manifestations exists.
In this study we report the clinical manifestations and provide a detailed immunological analysis of 8 late-onset FHL patients -6 patients with mutations in STXBP2 and 2 patients with mutations in UNC13D. We document that late-onset FHL can present with features typically associated with primary immunodeficiencies including characteristic immunological abnormalities that may manifest prior to the onset of HLH. In addition, we show that partial reconstitution of impaired NK cell degranulation upon stimulation with IL-2 and retained CTL cytotoxicity are important immunological features associated with atypical rather than with typical FHL.
Design and Methods

Patients
In Germany patients treated according to the international HLH treatment protocols (HLH-94, HLH-2004 ) are registered at the national study center in Hamburg, where genetic analysis for FHL is performed if indicated. Since 2008, a comprehensive immunological analysis was performed in more than 80 of these HLH-patients at the Centre of Chronic Immunodeficiency in Freiburg (Germany). For the present study, we included all patients with mutations in known FHL-associated genes diagnosed since 2008 with an onset of HLH (defined according to the criteria of the Histiocyte Society) beyond 2 years of age and survival without HSCT until at least 6 years of age (hereafter termed "atypical FHL"). A group of FHL patients presenting with HLH before 2 years of age ("typical FHL") and healthy blood donors were used as controls for the immunological assays. Written informed consent for genotyping, immunological studies and data collection was obtained from the patients or their legal guardians. The study was conducted according to the guidelines of the declaration of Helsinki and has been approved by the local institutional review board.
Cells
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation (PAN-Biotec, Aidenbach, Germany). PBMCs as well as the human erythroleukemia cell line K562 and the mouse leukemia cell line L1210 (ATCC, Manassas, USA) were maintained in complete medium (IMDM, 10% fetal calf serum (FCS) and 1% Penicillin/Streptomycin/Glutamine; all from Invitrogen, Carlsbad (CA), USA).
Antibodies and reagents
The following fluorochrome-conjugated antibodies were used for flow cytometry: anti-CD3- 
Cytotoxicity and degranulation assays
NK cell cytolytic activity was measured in a standard 51 Chromium release ( 51 Cr) assay on K562 targets and CTL cytotoxic function was analyzed in an anti-CD3 redirected-lysis assay on L1210 target cells as described previously (7) . NK-to-target and CTL-to-target ratios were calculated by multiplying the respective effector-to-target-ratio with the percentage of NK cells or CTLs in the effector cell suspension as determined by FACS analysis. Analysis of activation-induced degranulation was performed by detection of surface expression of CD107 on NK cells and CTLs (12, 13). In most patients, the degranulation assays were performed on several occasions. The mean value obtained in these assays is indicated in the figures.
Genetic analysis
Genomic DNA was isolated from peripheral blood samples using standard procedures. PCR products included the coding exons and adjacent intronic regions. Primer sequences have been published previously (STXBP2) (7) or are available upon request (UNC13D). Products were directly sequenced with BigDye Terminator v1.1 and run on an ABI PRISM 3100 genetic analyzer (both from Applied Biosystems, Carlsbad, (CA) USA).
Statistical analysis
Mann-Whitney's U-test was applied to compare the data on CD107 expression on NK cells between early-and late-onset FHL patients. and STX11 genes were excluded and a degranulation defect could clearly be demonstrated (see below), this patient was included in this study although a second mutation could not be identified. Ten typical FHL patients, seven with mutations in UNC13D and three with mutations in STXBP2 were used as controls for the cytotoxicity and degranulation assays.
None of these patients carried splice site mutations.
Clinical characteristics of patients with atypical FHL
The first episode of HLH occurred in the third or fourth year of life in three patients and in the 6 th year of life or later (as late as 34 years in a patient with UNC13D deficiency) in the remaining 5 patients (Table 1) . Three patients had a single episode of HLH. In the 34-year old patient, this episode was lethal, the two other patients had disease-free follow-up for 6 months and 2 years, respectively. The remaining 5 patients had recurrent flares of the disease with long intervals of disease-free remission and mostly good responses to therapy.
Primary EBV infection was a trigger for HLH in P1 and P4, while P3 initially presented with HLH-like symptoms that did not completely fulfill the HLH criteria, but developed the full clinical picture of HLH after primary EBV infection. All three of these patients developed chronic active EBV infection. Two other patients had apparently seroconverted to EBV without overt clinical symptoms, but eventually also developed chronic active EBV infection (P6, P7). In both of the latter patients, the development of HLH was associated with a massive increase in EBV viral load. NK cell degranulation was impaired to a similar extent in both patient groups, irrespective of whether they carried UNC13D or STXBP2 mutations ( Figure 1A-B) . Moreover, ex vivo NK cell cytotoxicity was reduced or absent in all but one of the typical and all of the atypical FHL patients ( Figure 1D ). Importantly, however, addition of IL-2 could partially restore NK cell degranulation to a level above 10% in all patients with atypical, but only in 1 of 9 patients with typical FHL ( Figure 1C ).
Impaired degranulation, but normal cytotoxic function of T cells in patients with atypical familial hemophagocytic lymphohistiocytosis
T cell degranulation and T cell cytotoxic function were analyzed using short-term (2 d and 7
d, respectively) stimulated PHA/IL-2 blasts. CTL degranulation was clearly impaired in all but one of the patients with atypical FHL and there was no significant difference between patients with a typical or atypical course of the disease (Figure 2A-B) . In contrast, T cell cytolytic activity was reduced or absent in typical FHL patients but in the normal range in all atypical FHL patients, irrespective of their genetic diagnosis ( Figure 2C ). Collectively, the data obtained in the NK cell and T cell cyotoxicity and degranulation studies provide a functional correlate for the atypical course of FHL in our patients.
Impaired B cell immunity in patients with late-onset familial hemophagocytic lymphohistiocytosis
Chronic hypogammaglobulinemia was documented in 4 of the 8 atypical FHL patients (1 FHL-3 patient and 3 FHL-5 patients) ( Figure 3A ), in three cases associated with a clinically relevant susceptibility to bacterial sinopulmonary infections that improved upon immunoglobulin substitution. Interestingly, IgG levels in P4 and P6 were normal before the first episode of HLH, but persistently decreased thereafter. P7 had persistently low IgG levels and an increased susceptibility to infections before developing HLH. In patients with common variable immunodeficiency (CVID), hypogammaglobulinemia is associated with a characteristic impairment of B cell differentiation (32) . We therefore analyzed the B cell phenotype in our patients. All patients were investigated outside an HLH episode. P5 and P8
(the latter being the only patient with a normal B cell phenotype) were investigated when receiving ciclosporin and steroids, but all other patients were analyzed when they were off any immunosuppressive therapy. P1 and P3 had such a severe reduction of their circulating The discrepancy between NK cell and CTL cytotoxicity in samples obtained from the same patients was unexpected. Since this was observed in patients with MUNC 13-4 deficiency as well as in patients with MUNC 18-2 deficiency, it cannot be ascribed to a particular molecular defect. Different molecular requirements for lytic granule release in NK cells versus CTL have so far not been described. We therefore consider it more likely that the differences reflect different pretreatment of the cells. While NK cell cytotoxicity was measured directly ex vivo, CTL had been cultured for 7 days in PHA and IL-2 before target cell lysis was assessed. This interpretation is supported by the finding that NK cell degranulation was partially restored by 48h prestimulation with IL-2. Such restoration of NK cell degranulation has previously been reported in FHL-4 patients (11, 12). Our findings show that this effect is not specific for SYNTAXIN-11 deficiency, but can also be observed in atypical MUNC13-4 and MUNC18-2 deficiency. Whether IL-2 stimulation improves degranulation and cytotoxicity by enhancing alternative splicing and/or exon skipping or by optimizing the residual cytotoxic potential of the affected cells remains unresolved. Whatever the mechanism, it might be relevant in vivo and thus contribute to a partially retained cytotoxicity associated with the milder and/or later presentation of our patients. In male patients presenting with HLH, X-linked lymphoproliferative disease (XLP) is an important differential diagnosis to FHL. We document that the phenotypic overlap between these diseases extends to other major phenotypes of XLP, i.e. lymphoma and hypogammaglobulinemia with chronic splenomegaly (37) (38) (39) . Moreover, all 5 patients infected with EBV fulfilled current diagnostic criteria for chronic active EBV infection (40) . A role for EBV in the chronic activation of T cells and macrophages has been well documented.
Seven out of seven atypical FHL-patients analyzed had low numbers of NKT cells, which is also considered a characteristic feature of XLP (33, 37, 38, 41, 42) 
